日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Clinical and Genomic Factors Associated with Elacestrant Outcomes in ESR1-Mutant Metastatic Breast Cancer

ESR1突变转移性乳腺癌中与依拉司特疗效相关的临床和基因组因素

Lloyd, Maxwell R; Weipert, Caroline M; Ali, Azka; Solomon, Sheila R; Saha, Jayati; Lipsyc-Sharf, Marla D; Hamilton, Erika P; Kalinsky, Kevin; Brufsky, Adam M; Bardia, Aditya; Zhang, Nicole; Wander, Seth A

Real-world effectiveness of palbociclib in combination with an aromatase inhibitor in HR+/HER2- bone-only metastatic breast cancer

帕博西尼联合芳香化酶抑制剂治疗HR+/HER2-骨转移性乳腺癌的真实世界疗效

Brufsky, Adam; Layman, Rachel M; Liu, Xianchen; Li, Benjamin; McRoy, Lynn; Cohen, Aaron B; Estevez, Melissa; Cottu, Paul; Curigliano, Giuseppe; Rugo, Hope S

Real-world progression-free survival 2 (PFS2) and tumor response of CDK4/6 inhibitors plus an aromatase inhibitor in patients with HR+/HER2- metastatic breast cancer in US routine clinical practice

美国常规临床实践中,CDK4/6抑制剂联合芳香化酶抑制剂治疗HR+/HER2-转移性乳腺癌患者的真实世界无进展生存期2(PFS2)和肿瘤反应

Rugo, Hope S; Brufsky, Adam; Layman, Rachel M; Liu, Xianchen; Li, Benjamin; McRoy, Lynn; Cohen, Aaron B; Estevez, Melissa; Lynce, Filipa; Cottu, Paul; Thill, Marc; Curigliano, Giuseppe

Prognostic value of visually and computationally assessed tumor-infiltrating lymphocytes in early-stage triple-negative breast cancer (TBCRC-030)

视觉和计算机评估的肿瘤浸润淋巴细胞在早期三阴性乳腺癌中的预后价值(TBCRC-030)

Nader-Marta, Guilherme; Chu, Xiangying; Mukhopadhyay, Satabhisa; Abramson, Vandana G; Brufsky, Adam; Stringer-Reasor, Erica Michelle; Dent, Susan Faye; Traina, Tiffany A; Carey, Lisa A; Rimawi, Mothaffar F; Specht, Jennifer M; Miller, Kathy D; Santa-Maria, Cesar Augusto; Dasgupta, Tathagata; Kurt, Busem Binboğa; DeMeo, Michelle; Krop, Ian E; Tung, Nadine M; Schnitt, Stuart J; Tayob, Nabihah; Mayer, Erica L

Comparative effectiveness of CDK4/6 inhibitors in metastatic breast cancer: using the target trial emulation framework to investigate overall survival in routine care

CDK4/6抑制剂在转移性乳腺癌中的比较疗效:利用目标试验模拟框架研究常规治疗中的总生存期

Brufsky, Adam M; Finn, Richard S; Metzger, Otto; Goncalves, Rodrigo; Huang-Bartlett, Cynthia; Sreenivasan, Sameet; Nur, Ula; Davies, Jessica; Grigorenko, Alex; Long, Gráinne H

Reply to: "Annual Versus Biennial Mammographic Screening" and "Breast Cancer Screening Interval: Effects of Proportions and Biases on Benefits"

回复:“年度与两年一次的乳腺X光检查”和“乳腺癌筛查间隔:比例和偏差对获益的影响”

Zuley, Margarita L; Bandos, Andriy I; Duffy, Stephen W; Logue, Durwin; Bhargava, Rohit; McAuliffe, Priscilla F; Brufsky, Adam M; Nishikawa, Robert M

Real-world palbociclib dose modifications and clinical outcomes in patients with HR+/HER2- metastatic breast cancer: A Flatiron Health database analysis

真实世界中帕博西尼剂量调整对HR+/HER2-转移性乳腺癌患者临床结局的影响:一项基于Flatiron Health数据库的分析

Layman, Rachel M; Liu, Xianchen; Li, Benjamin; McRoy, Lynn; Brufsky, Adam

Palbociclib treatment in patients with HR+/HER2- advanced or metastatic breast cancer and visceral metastasis: A systematic literature review

帕博西尼治疗HR+/HER2-晚期或转移性乳腺癌伴内脏转移患者:系统性文献综述

Radosa, Julia C; Cobo, Sara López-Tarruella; Dzieran, Johanna; Glastetter, Esther; Chen, Connie; Lingohr-Smith, Melissa; Pasupuleti, Vinay; Brufsky, Adam

Biomarker prediction of immunotherapy response in breast cancer: from single markers to multi-omics integration

乳腺癌免疫治疗反应的生物标志物预测:从单一标志物到多组学整合

Sanjari Moghaddam, Ali; Lu, Kit Y; Nasrollahi, Elham; Oji, Lovette; Homeniuk, Anna; Amosu, Oyindamola; Chelysheva, Daria; Brufsky, Adam M

Comparative efficacy of first- versus second-line CDK4/6 inhibition in hormone receptor-positive, HER2-negative metastatic breast cancer

一线与二线 CDK4/6 抑制剂治疗激素受体阳性、HER2 阴性转移性乳腺癌的疗效比较

Ravani, Lis Victoria; Bagheri, Zahra; Brufsky, Adam M; Michelon, Isabella; O'Regan, Ruth; Lustberg, Maryam; Han, Hyo; Wang, Ming; Wander, Seth A